Showing 2091-2100 of 3039 results for "".
- Shamir Glacier PLUS Metaform on 1.6 and 1.67 Now Availablehttps://modernod.com/news/shamir-glacier-plus-metaform-on-16-and-167-now-available/2481093/Shamir announced the availability of the new Glacier PLUS Metaform lens-coating technology, which uses fewer resources and chemicals in its production than its premium AR coating, making it an eco-friendly option for consumers. According to Shamir, features of the new len
- Clearside Biomedical Enters Into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for Up to $65 Millionhttps://modernod.com/news/clearside-biomedical-enters-into-non-dilutive-financing-agreement-with-healthcare-royalty-partners-for-up-to-65-million/2481020/Clearside Biomedical announced it has entered into an agreement with HealthCare Royalty Partners in a deal worth up to $65 million. Clearside intends to use the proceeds from the agreement to support ongoing clinical development of its pipeline, including CLS-AX (axitini
- New Book Now Available: "Cataract Surgery: Advanced Techniques for Complex and Complicated Cases"https://modernod.com/news/new-book-now-available-cataract-surgery-advanced-techniques-for-complex-and-complicated-cases/2481018/Renowned ophthalmologists Jorge Alio, MD, PhD, FEBOphth; Buchard Dick, MD, PhD, FEBOS-CR; and Bob Osher, MD, have edited a new book titled "Cataract Surgery in Complex and Complicated Cases." It includes a large number of videos that aims to enrich the didactic value
- Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Trianglehttps://modernod.com/news/atsena-therapeutics-announces-opening-of-new-office-and-laboratory-space-in-north-carolinas-research-triangle/2480994/Atsena Therapeutics announced the opening of its new office and laboratory in the Alexandria Center for Advanced Technologies–Research Triangle. The occasion was celebrated during a ribbon-cutting ceremony yesterday. The new state-of-the-art facility consist
- Xequel Bio Announces Positive Results from Phase 1b Study of iNexin, a Novel aCT1 Ophthalmic Solutionhttps://modernod.com/news/xequel-bio-announces-positive-results-from-phase-1b-study-of-inexin-a-novel-act1-ophthalmic-solution/2480963/Xequel Bio announced positive results from its phase 1b clinical trial with iNexin (aCT1 ophthalmic solution) for the treatment of corneal injury in patients with dry eye disease. The study demonstrated that iNexin was safe and well-tolerated at the doses tested, and ear
- Kuria Therapeutics and Scohia Pharma Announce Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activatorhttps://modernod.com/news/kuria-therapeutics-and-scohia-pharma-announce-licensing-agreement-for-ophthalmic-and-dermal-rights-to-sco-116-a-novel-nrf2-activator/2480933/Kuria Therapeutics and Japanese biotech company Scohia Pharma announced that the companies have entered into a licensing agreement under which Kuria may develop, manufacture, and commercialize worldwide the locally delivered formulations of SCO-116, one of Scohia's internally discov
- The Vision Council Announces that Version 3.13 of the Data Communication Standard is Now Availablehttps://modernod.com/news/the-vision-council-announces-that-version-313-of-the-data-communication-standard-is-now-available/2480893/The Vision Council announced the publication of Version 3.13 of the Standard for Data Communications. The standard, which is used by manufacturers of optical lab equipment and producers of software used in optical labs, was developed by The Vision Council’s Lens Proce
- Submissions Now Being Accepted for Innovation Stage Speakers and Content for Vision Expo West 2022https://modernod.com/news/submissions-now-being-accepted-for-innovation-stage-speakers-and-content-for-vision-expo-west-2022/2480883/The Vision Council and RX, co-organizers of Vision Expo, announced that submissions are being accepted for Innovation Stage speakers, presentations and panels for
- Allergan to Present New Data from its Portfolio of Eye Care Treatments at ARVOhttps://modernod.com/news/allergan-to-present-new-data-from-its-portfolio-of-eye-care-treatments-at-arvo/2480817/Allergan announced that it will present new data on Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the first and only FDA-approved eye drop for the treatment of presbyopia (age-related blurry near vision) in adults, and Durysta (bimatoprost
- Kala Pharmaceuticals Announces Eysuvis Now Covered on UnitedHealthcare Commercial and Cigna Medicarehttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-on-unitedhealthcare-commercial-and-cigna-medicare/2480681/Kala Pharmaceuticals announced that UnitedHealthcare, one of the largest commercial health care plans in the United States covering approximately 13 million people, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies eff